Clinical trial
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple…
NCT00012350 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00012350 |
|---|---|
| Title | Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma |
| Official title | Phase II Evaluation of FTI (R115777) (NSC 702818) in Treatment of Advanced Multiple Myeloma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH National Institutes of Health (NIH) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | FTI |
| Enrollment | 44 |
| Start date | Jan 1, 2001 |
| Primary completion | Sep 1, 2003 |
| Completion | Jan 1, 2010 |
| First posted | May 20, 2004 |
| Last update posted | Oct 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: